RenovoRx reports Q1 EPS (8c), consensus (8c)

Reports Q1 revenue $197K, consensus $183.3K. “I am pleased to report a milestone event for RenovoRx (RNXT): Q1 was our first full quarter of RenovoCath commercial sales, generating approximately $200,000 in revenue. Moreover, this revenue exceeded our internal expectations, and we anticipate this positive trend to continue as we expect sequential quarterly growth for the foreseeable future,” said Shaun Bagai, CEO of RenovoRx. “Additionally, we believe that the approximately twenty cancer centers that have used RenovoCath as part of our ongoing Phase III TIGeR-PaC trial could also become potential customers after the planned completion of trial enrollment later this year. Our enthusiasm about the value proposition of our company has never been higher as we dual track the growth of our commercial efforts and progress our clinical trial towards important milestones later this year.”